TNXP
NASDAQ · Biotechnology
Tonix Pharmaceuticals Holdin
$9.74
-0.16 (-1.62%)
Financial Highlights (FY 2026)
Revenue
26.04M
Net Income
-246,357,043
Gross Margin
49.3%
Profit Margin
-946.2%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 49.3% | 59.2% | 59.2% | 59.2% |
| Operating Margin | -975.0% | -23.9% | -24.9% | -24.3% |
| Profit Margin | -946.2% | -24.5% | -29.4% | -31.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 26.04M | 84.57M | 86.26M | 76.53M |
| Gross Profit | 12.85M | 50.02M | 51.02M | 45.27M |
| Operating Income | -253,844,799 | -20,221,333 | -21,451,311 | -18,634,068 |
| Net Income | -246,357,043 | -20,699,385 | -25,319,011 | -23,908,785 |
| Gross Margin | 49.3% | 59.2% | 59.2% | 59.2% |
| Operating Margin | -975.0% | -23.9% | -24.9% | -24.3% |
| Profit Margin | -946.2% | -24.5% | -29.4% | -31.2% |
| Rev Growth | — | +3.2% | +20.0% | +0.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 97.43M | 108.81M | 97.98M |
| Total Equity | — | 167.70M | 160.32M | 155.36M |
| D/E Ratio | — | 0.58 | 0.68 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -250,029,244 | -24,990,141 | -25,196,528 | -24,930,968 |
| Free Cash Flow | — | -20,292,095 | -20,848,476 | -17,728,438 |